- Home
- CLEU vs ALZN Comparison
CLEU vs ALZN Comparison
Compare CLEU & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLEU
- ALZN
- Stock Information
- Founded
- CLEU 2011
- ALZN 2016
- Country
- CLEU China
- ALZN United States
- Employees
- CLEU N/A
- ALZN N/A
- Industry
- CLEU Other Consumer Services
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- CLEU Real Estate
- ALZN Health Care
- Exchange
- CLEU Nasdaq
- ALZN Nasdaq
- Market Cap
- CLEU 6.4M
- ALZN 7.0M
- IPO Year
- CLEU 2020
- ALZN 2021
- Fundamental
- Price
- CLEU $0.21
- ALZN $1.36
- Analyst Decision
- CLEU
- ALZN Strong Buy
- Analyst Count
- CLEU 0
- ALZN 1
- Target Price
- CLEU N/A
- ALZN $35.00
- AVG Volume (30 Days)
- CLEU 182.3K
- ALZN 123.2K
- Earning Date
- CLEU 11-26-2024
- ALZN 12-13-2024
- Dividend Yield
- CLEU N/A
- ALZN N/A
- EPS Growth
- CLEU N/A
- ALZN N/A
- EPS
- CLEU N/A
- ALZN N/A
- Revenue
- CLEU $2,413,409.00
- ALZN N/A
- Revenue This Year
- CLEU N/A
- ALZN N/A
- Revenue Next Year
- CLEU N/A
- ALZN N/A
- P/E Ratio
- CLEU N/A
- ALZN N/A
- Revenue Growth
- CLEU N/A
- ALZN N/A
- 52 Week Low
- CLEU $0.20
- ALZN $1.31
- 52 Week High
- CLEU $4.74
- ALZN $19.20
- Technical
- Relative Strength Index (RSI)
- CLEU 29.56
- ALZN 32.37
- Support Level
- CLEU $0.23
- ALZN $1.43
- Resistance Level
- CLEU $0.24
- ALZN $1.59
- Average True Range (ATR)
- CLEU 0.02
- ALZN 0.10
- MACD
- CLEU -0.00
- ALZN -0.01
- Stochastic Oscillator
- CLEU 9.62
- ALZN 13.16
About CLEU China Liberal Education Holdings Limited
China Liberal Education Holdings Ltd is an educational service provider operating in China. The company's operating segment includes Sino-foreign Jointly Managed Academic Programs, textbooks and course material sales, Overseas Study Consulting Services, Technological Consulting Services for Smart Campus Solutions and Tailored Job Readiness Training Services. Geographically, it derives revenue from China.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.